Last deal

$4.83M

Amount

Venture - Series Unknown

Stage

20.04.2016

Date

3

all rounds

$13.7M

Total amount

date founded

Financing round

General

About Company
CLS is a drug discovery company specializing in developing novel kinase inhibitors for human and animal healthcare.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2010

Number of employees

Company Type

For Profit

Last funding type

Venture - Series Unknown

IPO status

Private

Description

CLS focuses on rational drug design to discover and develop unique kinase inhibitors that target signal transduction enzymes involved in cancer growth, chronic inflammation, and autoimmune diseases. Their team of experienced experts with pharmaceutical backgrounds allows them to explore strategies and targets outside the traditional pharmaceutical focus. CLS aims to develop a pipeline of drug programs through discovery, development, partnership, and repetition. They also collaborate with scientific and business partners to enhance their success.
Similar Companies
1000
Carna Biosciences

Carna Biosciences

Carna Biosciences develops innovative medicines to improve human health.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

Chuo Ward, Sapporo, Hokkaido, Japan

total rounds

1
ImQuest Life Sciences

ImQuest Life Sciences

ImQuest Life Sciences is developing novel drugs to combat infectious diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Shaanxi, China
QBiotics

QBiotics

QBiotics develops plant-based treatments for challenging medical conditions in humans and animals.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

Yungaburra QLD 4884, Australia
Imago BioSciences

Imago BioSciences

Imago is a clinical stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms (MPNs).

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

San Carlos, CA, USA

total rounds

3

total raised

$146.5M
M&A Details
1

Acquired by

Aclaris Therapeutics

announced date

08.08.2017

price

$100M

Financials

Funding Rounds
7
3

Number of Funding Rounds

$13.7M

Money Raised

Their latest funding was raised on 20.04.2016. Their latest round Venture - Series Unknown

Date 
Funding Round 
Investors 
Money Raised 
Lead 
20.04.2016
$4.83M
28.07.2015
5
$2.4M
19.02.2014
1
$1M
Co-Investors
Investors
7
1

Number of lead investors

7

Number of investors

Investor 
Lead 
Round 
Partners 
No
Series A, Series B
No
Series A, Series B
BioGenerator

BioGenerator

BioGenerator provides seed investment to startup bioscience companies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

St. Louis, MO, USA

total rounds

2

total raised

$750K

count Of Investments

70

count Of Exists

5
Epidarex Capital

Epidarex Capital

Epidarex Capital is a venture capital firm that invests in early-stage life science and health technology companies.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Venture Capital, Biotechnology, Financial Services

Location

Bethesda, MD, USA

count Of Investments

39

count Of Exists

2
Missouri Technology Corporation

Missouri Technology Corporation

Missouri Technology Corporation is a venture capital firm that promotes entrepreneurship and fosters the growth of high-tech companies.

Sector

General Industrials

Subsector

Diversified Industrials

Location

Jefferson City, MO, USA

count Of Investments

103

count Of Exists

9

People

Founders
1
Joseph Monahan
Joseph Monahan

Joseph Monahan

Monahan founded Confluence in 2010 following a successful 28 year career in the pharmaceutical industry. Prior to starting Confluence he held multiple research leadership positions at Pfizer Inc., including Executive Director Inflammation Research, Global Kinase Platform Leadership Team, Site Head of Enzymology and Biophysics and Inflammation Research Clinical Development Lead. Monahan has successfully led the advancement of project portfolios from early discovery through Phase 1 and 2 clinical development. Monahan has held adjunct and visiting professor positions at Washington University Medical School and UCLA School of Medicine, respectively, has published over 75 peer reviewed publications and is co-inventor on 12 patents.

current job

Confluence Discovery Technologies
Confluence Discovery Technologies

organization founded

2

Joseph Monahan

Employee Profiles
4
Paul Changelian

Paul Changelian

Director of Biology

Joseph Monahan

Joseph Monahan

Chief Scientific Officer & Founder

Robert Beardsley

Robert Beardsley

Various Roles

Activity

Recent News
0